References
- Arseneau J. C., Sponzo R. W., Levin D. L., et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease: possible association with intensive therapy. N. Engl. J. Med. 1972; 287: 1119–1122
- Coleman C. N., Williams C. J., Flint A., et al. Hematologic neoplasia in patients treated for Hodgkin's disease. N. Engl. J. Med. 1977; 297: 1249–1252
- Kaldor J. M., Day N. E., Clarke E. A., et al. Leukemia following Hodgkin's disease. N. Engl. J. Med. 1990; 322: 7–13
- Pedersen-Bjergaard J., Larsen S. O. Incidence of acute non-lymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N. Engl. J. Med. 1982; 307: 965–971
- Salvagno L., Simonato L., Sorarù M., et al. Secondary leukemia following treatment for Hodgkin's disease. Tumori. 1993; 79: 103–107
- Blayney D. W., Longo D. L., Young R. C., et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N. Engl. J. Med. 1987; 316: 710–714
- Tucker M. A., Coleman C. N., Cox R. S., et al. Risk of a second cancer after treatment for Hodgkin's disease. N. Engl. J. Med. 1988; 318: 76–81
- Bouabdallah K., Marit G., Reiffers J., et al. Hodgkin's disease and secondary Philadelphia chromosome positive chronic myelogenous leukemia. Cancer Genet. Cytogenet. 1991; 55: 277–278
- Verhoef G. E. G., Demuynek H., Stul M. S., et al. Philadelphia chromosome-positive chronic myelogenous leukemia in treated Hodgkin's disease. Cancer Genet. Cytogenet. 1990; 49: 171–176
- Swaim R., Windschitl H. E., Doscherholmen A., et al. Chronic myelogenous leukemia in Hodgkin's disease: immunofluorescence of cells. Cancer 1971; 27: 569–573
- Whang-Peng J., Young R. C., Lee E. C., et al. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988; 71: 403–414
- De Vita V. T., Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 1970; 73: 891–895
- Baccarani M., Bosi A., Papa G. Second malignancy in patients treated for Hodgkin's disease. Cancer 1980; 46: 1735–1740
- Coleman C. N., Dixon D. O. Second malignancies complicating Hodgkin's disease: A Southwest Oncology Group 10-year follow-up. Cancer Treat. Rep. 1982; 66: 1023–1033
- Coleman C. N., Kaplan H. S., Cox R., et al. Leukemias, non-Hodgkin's lymphomas and solid tumors in patients treated for Hodgkin's disease. Cancer Surveys 1982; 1: 733–744
- Moloney W. C. Radiogenic leukemia revisited. Blood 1987; 70: 905–908
- Nowell P. C., Finan J. B., Weiss A. Karyotypic and clinical progression in chronic myelogenous leukemia after 30 years. Cancer Genet. Cytogenet. 1992; 60: 96–98
- Najean Y., Miclea M., Tanzer J., et al. Chronic myelocytic leukemia with unusual (27 years) complete remission terminating in acute undifferentiated leukemia: a clinical and karyotypic study. Leukemia 1991; 5: 621–623
- Prischl F. C., Haas O. A., Lion T., et al. Duration of First remission as an indicator of long term survival in chronic myelogenous leukemia. Br. J. Haematol. 1989; 71: 337–342
- Van Leuween F. E., Somers R., Hart A. A. M. Splenectomy in Hodgkin's disease and secondary leukemias. Lancet 1987; 2: 210–211
- Medical Research Council's Working Party for Therapeutic Trials in Leukemia. Randomized trial of splenectomy in Ph1-positive chronic granulocytic leukemia, including an analysis of prognostic factors. Br. J. Haematol. 1983; 54: 415–430
- The Italian Cooperative Study Group on CML. Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. Cancer 1984; 54: 333–338